Compare TG Therapeutics Inc (TGTX) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs T-Mobile Us Inc — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while T-Mobile Us Inc trades at $148.58 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 22.5× TG Therapeutics Inc's market cap, and T-Mobile Us Inc pays a 2.73% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and T-Mobile Us Inc for 84 Days on average.
| TGTX | TMUS | |
|---|---|---|
Market Cap | $8.16B | $183.76B |
Volume | 1,735,121 | 4,294,650 |
Sector | Health | Media |
52-Week High | $59.06 | $230.06 |
52-Week Low | $26.94 | $161.73 |
Typical Hold Time | 16 Days | 84 Days |
Enterprise Value | $8.37B | $300.37B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
T-Mobile US (TMUS) trades at $148.58, down 11.36% over 24 hours, reflecting recent market pressure. The stock shows strong fundamental health with revenue growth to $88.31B in 2025 and a net income margin of 11.45%. Analyst consensus is strongly bullish with a $231.10 price target, supported by a 15% dividend hike announced in September 2026. Technical indicators are mixed, with a bearish moving average signal but neutral oscillators, while recent news highlights AI-driven 5G advancements and a joint venture with AT&T and Verizon to expand coverage.
The outlook for TMUS is positive due to robust earnings beats, strategic initiatives, and solid cash flow, though risks include high debt levels and competitive pressures. Investors may find value in its growth trajectory and dividend increases, but should monitor debt management and industry competition closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
